FORM PTO 1449		19 US Department of Commerce Patent and Trademark Office		ATTY DOCKET NO.: MEDINI1400		APPL	APPLICATION NO.: 09/602,688	
4	-		·	APPLICANT(S):	LAI A	ND WANG		
INFORMAT		DISCLOSURE STA	TEMENT	FILING DATE: JUNE 23,	2000	GROU	JP ART UNIT: UNASSIGNED	
ON 3 0 5000 F			U.S. PATE	ENT DOCUMENTS	}	·		
EXAM.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE	
TAIL/C	AA							

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	BA						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

A		CA	Bjarnason, I et al., "Side Effects of Nonsteroidal Anti-inflammatory Drugs on the Small and Large Intestine in Humans", Special Reports and Reviews, Gastroenterology, 104:1832-1847 (1993).
	•	СВ	Carson, J.L. et al, "The Relative Gastrointestinal Toxicity of the Nonsteroidal Anti-inflammatory Drugs", <i>Arch Intern Med</i> , Vol 147, June (1987).
		CC	Glaser, K. et al, "Etodolac Selectively Inhibits Human Prostaglandin G/H Synthase 2 (PGHS-2) Versus Human PGHS-1", European Journal of Pharmacology 281, 107-111, (1995).
	1	CD	Graham, D.Y., MD., et al, "Nonsteroidal Anti-inflammatory Effect of Sulindac Sulfoxide and Sulfide on Gastric Mucosa", <i>Clin Pharmacol Ther</i> , 38: 65-70, (1985).
10	T.	CE	Kaplan-Machlis, B. et al., "The Cyclooxygenase-2 Inhibitors: Safety and Effectiveness", <i>The Annals of Pharmacotheraphy</i> , Vol. 33, 979-88, September (1999).

EXAMINER Story of DA'	9-13-2001
-----------------------	-----------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO.: MEDINI1400	APPLICATION NO.: 09/602,688	
Nov 3 0 2000 &	APPLICANT(S): LAI AND WANG		
INFORMATION DISCLOSURE STATEMENT BY APPLACANT	FILING DATE: JUNE 23, 2000	GROUP ART UNIT: UNASSIGNED	

TOT		CF	Kargman, S., et al., "Characterization of Prostaglandin G/H Synthase 1 and 2 in Rat, Dog, Monkey, and Human Gastrointestinal Tracts", Gastroenterology, American Gastroenterological Association, 111: 445-454, (1996).
(Cyclooxygenase) Isozymes by Aspirin and Other Non-steroidal Anti-infl		Meade, E.A., et al., "Differential Inhibition of Prostaglandin Endoperoxide Synthase (Cyclooxygenase) Isozymes by Aspirin and Other Non-steroidal Anti-inflammatory Drugs", <i>The Journal of Biological Chemistry, The American Society for Biochemistry and Molecular Biology, Inc.</i> , Vol. 268, No. 9, 6610-6614, March 25 (1993).	
		СН	Mitchell, J.A., et al., "Selectivity of Nonsteroidal Antiinflammatory Drugs as Inhibitors of Constitutive and Inducible Cyclooxygenase", <i>Proc. Natl. Acad. Sci. USA</i> , Pharmacology, Vol. 90, 11693-11697, December (1994).
		CI	Onoe, Y, et al., "IL-13 and IL-4 Inhibit Bone Resorption by Suppressing Cyclooxygenase-2-Dependent Prostaglandin Synthesis in Osteoblasts", <i>The Journal of Immunology</i> , The American Association of Immunologists, 156: 758-764, (1996).
	,	CJ	Slater, D.M., et al., "Expression of Cyclooxygenase Types 1 and 2 in Human Fetal Membranes at Term", <i>Am J Obstet Gynecol</i> , Vol 172, No. 1, Part 1, 172: 77-82 (1995).
\ \ \		CK	Soll, A.H., MD, et al., "Nonsteroidal Anti-inflmmatory Drugs and Peptic Ulcer Disease", Annals of Internal Medicine (UCLA Conference), 114: 307-319, (1991).
A	THE	CL	Wallace, J.L. "Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years", <i>Gastroenterology, The American Gastroenterological Association</i> , 112: 1000-1016, (1997).

EXAMINER Thousand D. Angel	DATE CONSIDERED $69-/3-5001$

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.